Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for sharing the link.
Bought in this morning @ .775
1st time owner of URRE... I hope it treats me right.
We are looking to hire... very positive sign.
The 3 month daily candlestick chart looks ready for a move... which direction? My fingers are crossed.
Its time to bust out of this .60 - .65 range to retest that .80
Looking good here lately...
BioTime to Produce Stem Cells for Research in Muscle Disorders
http://ih.advfn.com/p.php?pid=nmona&article=50595509&symbol=BTX
Ok... lets move on and get the focus back on NVIV.
NVIV LAST 2.46 -0.23 -8.55% VOLUME 913,503
I am far from an expert or day trader and actually just wanted you to realize that selling the shares was a wise decision. But you just get angry and resort to personal attacks because you are unable to admit that you overeacted after you sold and it went up a little... who seems under 21? Just for future forum knowledge, dont take ones claimed position size as a guage of investment experience. There are people who lurk on these sites that claim they own more than they do and then there are knowledgeable investors who say they own less than they do to avoid the attention the others seek. Those who claim they own more than they do are usually the ones who post that the company will be worth billions and the pps will be 100.
Would of... that mind set goes with could of & should of. In hind sight we always can find a better path or way. The point is you have to do what you can live with. I sold enough shares to have nothing invested... no risk at all in a stock I bought that took off overnight. I knew little about this company but the chart looked ready to make a move so I took a chance and it did. I am not a greedy person and I know 9 out of 10 times its a short term run followed by a pullback that leaves bagholders who "believed" it was or is the real deal. I now make trades and accumulate free shares whenever possible. I can tell you that 9 out of 10 times I get a chance to buy back the shares I sold at a lower price then I sold them. When they go higher after I sell, I am happy because my free shares are making me money and I "hope" its the real deal. When they go lower after I sell, I am happy because I then have the option to buy back shares at a lower price and make money again. In this case with NVIV of course I would of held on to all my shares if I knew it would hit $3+, but I am happy with my position and my decision to play it as I have. The point is do what you want to do, dont ask for advice from others then blam them for your decision. You did the right thing by selling those shares and I hope you learned a valuable lesson today that you can apply to your future trades. In your post you say I lost when in reality I cannot lose. You also say its all just gambling if you "believe" and you are right. If you believe that because you believe in a company it will just continue to go up, you will eventually get hurt on some form of suprise. So I suggest that you lean towards taking the money when its there and always take your investment out on huge percentage gains... but you may just consider that weak... good LUCK.
Now is the time to apoligize to the "weak" and realize the trading possibilities of long and short term investing in NVIV. By selling at 3.04 a share on 12/23/11 you now have the chance to buy them back considerably lower... like $490 dollars lower at the 2.55 low of today, which is the very next open market day of trading due to the holiday. Plus you would be making more money already with the pps at 2.78 as I write this. Be open minded and dont panic immediately after acting.
Come on... Lets see a new high for the day... Lets hit 3.25
When a CEO’s Personal Interest Inspires a Company’s Mission (OTC:NVIV)
http://www.smallcapnetwork.com/When-a-CEO-s-Personal-Interest-Inspires-a-Company-s-Mission-OTC-NVIV/s/via/14/article/view/p/mid/1/id/442/
Another lovely day in the NVIV neighborhood. Volume looking good.
Or put a stop loss @ 2.60 on half of your shares. All 3 scenerios = no possible way for you to lose your @$$.
My own personal opionion is to trade 1/2 your upside to eliminate any chance of downside. Sell half your shares anywhere over $2.60 and ride your free shares. If it goes up you will say "what if" but you will still be happy its going up, if it goes down you will be happy you cashed in and now have the cash to buy more at cheaper prices. I have learned to not dwell on the possible upside scenerio and focus on what currently is. You currently have a double, lock it in as a great trade and sit back while enjoying any future movement. Thats me sharing that as a fellow investor, I dont want anyone to sell a stock I own, but I want all of us little guys to make money when we can and not lose our @$$ when we can completely avoid it. Please only do what you can live with, because I do hope NVIV keeps going up!
Doing great... I have not increased my position in this company. I am in set it and forget it mode with the freebies I have accumulated. I hope this company achieves everything they set out to do. The chart looks great and it should be interesting to watch unfold. Everyone please share any and all info or media coverage you find... Happy Holidays
BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
http://ih.advfn.com/p.php?pid=nmona&article=50506269&symbol=BTX
It might just be BioTime! Nice day here, interested to see if news comes out soon. Someone might know something we dont.
Google finance says the daily average is 383,988. It has traded 354,583 already by 11:36am. It is up 15.53% so far, not bad, should be a good day.
The 6 month daily chart looks ready to move, but we need volume to breakout. I hope we can retest the previous high and sustain a move through it. We shall see
Bioheart Partners With Stemlogix to Offer Products to the Veterinary Market
http://ih.advfn.com/p.php?pid=nmona&article=50485922&symbol=BHRT
Bioheart Files With the FDA to Begin the ANGEL Trial
http://ih.advfn.com/p.php?pid=nmona&article=50316355&symbol=BHRT
No apology needed, everyone is entitled to his or her opinion. Lets just try to keep usernames out of our posts and keep the info we share factual instead of opinionated. I think anyone who spends their time posting here wants this company to do well so injured people can be helped and we can make some cash by investing in the company in its early stages.
InVivo Therapeutics Executes Deal for New, World-Class Global Corporate Headquarters Including Research & cGMP Manufacturing ...
http://ih.advfn.com/p.php?pid=nmona&article=50264253&symbol=NVIV
It is FURTHER ORDERED that the hearing currently scheduled for December 5, 2011, is POSTPONED, and a prehearing conference as to Stelax Industries, Ltd., Stem Cell Innovations, Inc., and Surfect Holdings, Inc., will be held by telephone on December 27, 2011, at
2:00 p.m. EST, with the Division making arrangements for the call.
The funny thing is I am long, holding long term "FREE" shares... I have traded myself into a position that I cant get hurt/burnt, I am playing with the houses money. This guy/girl is just looking for people to respond, next is the "this is my final post" BullS... classic forum igor that pops up when they stumble onto the seen a day late and a dollar short mad at those who were in before the price increase. They buy at the top, the price pulls back... they get that sick feeling of "Wow, I just jumped right in, maybe I should've looked before I jumped"... they fear being a bagholder so they make outrageous and false/unsupported/opinionated claims. After reading through past posts they bash anyone who might sell or has sold because now THEY are forced to be a long term holder due to THEIR current losses. When it goes up and he/she breaks even or has a small profit he/she will sell due to fear of possibly being in the red again. Maybe then this igor will move on, but I doubt it, occasionally they will stop buy to act like they still own if its up and if its down they will say things have changed... I sold, get out. Same story different angle.
BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts and Glaucoma
http://ih.advfn.com/p.php?pid=nmona&article=50239715&symbol=BLTI
Looking good here... it makes some decent price swings throughout the day which presents some nice trading opportunities. I will be keeping my core position and adding more free shares to it through short term trades when the opportunities arise. So far so good. garywoodruff... relax buddy, your overly excited... put down the redbull and realize we are all here to invest/make money by owning NVIV shares.
I am, but i will be honest... I thought about selling over $2 and I should have. But I would have bought back in at the end of the day.
5 Small Stocks With Home-Run Potential
Biolase Technology (Nasdaq: BLTI)
Recent price: $3.03
I first profiled this dental technology company in January, when shares traded at about $1.50. The stock quickly moved up to a 52-week high of about $6.85 soon thereafter. A 50% pullback from that peak leads me to again remind investors of the compelling value in this stock.
Under the tutelage of fresh management that came aboard in 2009, quarterly results keep getting stronger. Sales are expected to more than double this year to $54 million in comparison with last year, and rise another 30%-40% in 2012 as sales channels are tweaked.
This stock is no longer simply a story about dentistry. Look for Biolase to release new laser-based devices in the fields of ophthalmology, orthopedics and aesthetics in 2012. This means profit growth will be erratic during the next two years as Biolase invests in these new vertical niches. This also means that (projected) $75 million revenue base in 2012 could become a $150 million revenue base in a few years. I look for this stock to revisit the 52-week high of $6.85 during the next 12 months.
http://seekingalpha.com/article/308471-5-small-stocks-with-home-run-potential
I am hanging on long term to the shares I have now. Now the spreads are alot tighter and the volume is there with plenty more on the way. The first day I bought I had been watching for a while and never saw any action... then a pulse, so I bought. The next morning it flew with wide spreads on no news so I did the wise thing and took my 40+% profit and eventually ended the day with my long term shares. So I am officially a long from here on out.
I originally bought 2000 @ .80 at the end of the day.
I sold them all for 40+% profit the next morning.
Waited for it to pull back a little and bought back 500 shares of the best variety... FREE and kept the rest of the cash I made.
Staying small because I am getting a little tired of this sector. It has been a roller coaster with ACTC and GERN over the years.
InVivo Therapeutics Holdings Corp. (NVIV); Geron’s Exit from Stem Cell Research Bodes Well for the Company
By Mark Spencer
Published: November 16, 2011 12:06:48 PM PST
Print Email
0 Comment(s)- Post a Comment
Rating
StockHQ:
GERN
$1.62-$0.13-7.43%
NVIV
$1.90+$0.59+45.04%
Geron Corporation (NASDAQ: GERN), an undisputed leader in stem cell research, earlier this week announced that it is scrapping its stem cell research program due to high costs and commercial uncertainty for the field.
Geron said on Monday that it would not enroll new patients for study of a stem cell-based treatment for spinal cord injury. The company also said that it is planning to sell its stem cell program.
Geron was a pioneer in stem cell research and the company also had the necessary cash on its balance sheet to conduct research. Geron’s departure is a huge blow to the field of stem cell research. However, the move bodes well for one company; InVivo Therapeutics Holdings Corp. (OTC: NVIV), a Cambridge, Massachusetts-based biotechnology company. No surprise that InVivo shares have gone through the roof since Geron’s announcement to exit stem cell research.
Like Geron, NVIV is also developing a stem cell-based therapy for treatment of spinal cord injury. NVIV is currently developing a novel biopolymer scaffolding device to treat spinal cord injury.
So why is Geron’s departure good news for InVivo? One simple reason; investors who were looking to gain exposure to the fast growing field of stem cell research were betting mainly on Geron as the company was considered a leader in the field. But, with Geron now gone, investors have very limited options if they seek to gain exposure to stem cell research and NVIV is one of them. The surge in NVIV shares this week suggests that some of the investor money from Geron has already moved into the company.
NVIV is a pure-play stem cell research company. More importantly, it is focusing on the same area, spinal cord injury, like Geron. Recently, NVIV even appinted Dr. Edward Wirth, who was the Medical Director for Regenerative Medicine at Geron and led the first ever human embryonic stem cell trial, as its new Chief Scientific Officer.
On Tuesday InVivo provided an update on its business. The company said that it has submitted an IDE and is awaiting FDA clearance to begin a human clinical study with its proprietary biopolymer scaffolding device for acute spinal cord injury.
They are now the frontrunner on bringing a product to market that may be able to prevent/stop/fix paralysis due to a spinal cord injury. Geron was the leader but recently stopped their human stem cell trial to focus on other closer to market products.
Glad I bought back in... looking good.
BIOLASE Declares Stock Dividend for 2011 Fourth Quarter
http://ih.advfn.com/p.php?pid=nmona&article=49955016&symbol=BLTI
BioTime Cell Information Now Available in GeneCards®
http://ih.advfn.com/p.php?pid=nmona&article=49931139&symbol=BTX
Dryships Is A Steal At Current Prices
http://seekingalpha.com/article/306131-dryships-is-a-steal-at-current-prices
http://www.smallcapnetwork.com/The-Stem-Cell-Game-Just-Changed-CYTX-ACTC-GERN-Compared-Contrasted/s/via/1789/article/view/p/mid/3/id/65/
Enter Advanced Cell Technology, which in many ways brings together the best of both approaches. It's devised a way to extract one blood cell from an embryo, which doesn't destroy the embryo. From that one embryonic stem cell, however, ACTC can create some amazing treatments... more so than it may be able to do with mere fat tissue. The 'big enchilada' is its retinal pigment epithelium trial, which is the creation of retinal cells using this single-cell extraction process with the intent of treating macular degeneration. The trials have recently been given the Phase I green light in Europe (where the regimen has ale been given an orphan drug designation), and are already underway in the United States.
The upside to Advanced Cell Technology's treatment is two-fold. One, it could literally cure blindness for millions, and two, it potentially negates a great deal of the controversy for all embryonic stem cell research. Critics of the practice still argue it's wrong to rob an embryo of any of its cells, but the argument has been greatly muffled for the obvious reason...the embryo still survives.
ACTC is also using the extraction technique as part of R&D on treatments for heart disease and circulatory disorders. The former is ready for Phase II trials in the United States, while the latter could be approved for Phase I within a few months.
It's still a little soon to call Advanced Cell Technology, Inc. an investment-worthy game-changer, though it wouldn't be too soon to start thinking along those lines. While the company only has a handful of trials, its single-blastomere cell-extraction technique could open all kinds of doors. And yes, the company's procedure is protected under intellectual property rights.
Here in the shadow of a 35% dip since May could be the right time for newcomers to take a swing on a compelling biotech idea.